Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01514955
Other study ID # IMRT / 25027
Secondary ID ACRI PILOT GRANT
Status Withdrawn
Phase Phase 1
First received December 8, 2011
Last updated February 24, 2016
Start date November 2009
Est. completion date December 2011

Study information

Verified date January 2012
Source AHS Cancer Control Alberta
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Main cause of mortality in cervix cancer is local relapse in the pelvis. Since distant metastasis is quiet rare, increasing local control in the pelvis can directly translate into improvement in survival. Obstacles in front of this approach is the dose limitation to normal organs located in the pelvis adjacent to the tumor. 3-D MRI based EBRT and Brachytherapy will grant safe delivery of more conformal higher doses of radiation to the tumor and allowing sparing of the normal structures.


Description:

A total of 10 patients with a diagnosis of locally advanced cervical carcinoma will be enrolled. After diagnosis and written informed consent, patients will undergo investigations prior to treatment planning, including CT imaging as per standard of care. In addition, patients will have an MRI of the pelvis + PET scan + EUA and gold seeds insertion to verify pelvic organs movement and EB-IMRT with daily cone beam CT. Brachytherapy treatment planning will be based on MRI imaging with the applicator in situ.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-chemo-therapy including MRI guided BT. (stage IB2 bulky disease-stage IVa)

- Staging according to FIGO and TNM guidelines

- Positive biopsy showing squamous cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix

- No pelvic nodes > 2cm

- MRI of pelvis at diagnosis

- MRI of the retroperitoneal space and abdomen at diagnosis

- MRI with applicator in place at time of BT

- Age 18-70 years

- Patient informed consent

Exclusion Criteria:

- Pelvic nodes > 2cm

- Previous pelvic or abdominal radiotherapy

- Previous total or partial hysterectomy

- Combination of preoperative radiotherapy with surgery

- Patients receiving neo-adjuvant chemotherapy

- Patients receiving BT only

- Contraindications to MRI

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Radiation:
Gold seeds insertion to detect movements at pelvis

Image guided MRI based RT (IMRT+Brachytherapy)


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
AHS Cancer Control Alberta Cross Cancer Institute

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility parameters One year
Secondary Response rate, acute and late toxicity, local control rate, survival Five years No
Secondary Dosimetric comparison between 2D and 3D Brachytherapy treatment planning No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03225443 - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy N/A
Recruiting NCT06079671 - Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Phase 3
Completed NCT05059119 - Rectovaginal Fistula in Post-Radiotherapy Advanced Cervical Cancer Patients
Recruiting NCT06055738 - Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC Phase 2
Recruiting NCT06156514 - Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer Phase 3
Completed NCT03298893 - Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months Phase 1/Phase 2
Recruiting NCT05950087 - Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Recruiting NCT04884906 - Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer Phase 2
Not yet recruiting NCT05799469 - Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT05311566 - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Phase 2
Terminated NCT02045433 - Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT06237257 - A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer Phase 2
Not yet recruiting NCT06288373 - Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Phase 2/Phase 3
Not yet recruiting NCT06288360 - Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Phase 2
Recruiting NCT06068387 - A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis N/A
Recruiting NCT05378087 - Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer N/A
Recruiting NCT03963882 - NAC Followed by RH for the Treatment of LACC Phase 2
Recruiting NCT01938105 - Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer Phase 2
Active, not recruiting NCT01793701 - Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2
Completed NCT01230996 - Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2